Translation, Cross-cultural Adaptation and Validation of PRO-CTCAE for Italian-speaking Cancer Patients

NCT ID: NCT02381054

Last Updated: 2017-06-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

233 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-05-31

Study Completion Date

2017-06-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to see if the Italian language version of a questionnaire about symptoms that patients may have during cancer treatment is understandable to Italian speaking patients. The questionnaire is called the PRO-CTCAE, and was originally developed at the U.S. National Cancer Institute to help get information about patients' symptoms directly from the patients themselves. The Italian version of the questionnaire will be used in future studies to gain a better understanding of patient symptoms.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be conducted in two steps. The first is the Italian translation and cross cultural adaptation of the original US NCI's version of the PRO-CTCAE questionnaire. The questionnaire will be translated and administered to a sample of 96 Italian patients. After protocol amendment in November 2016, the second step was modified and consists of test-retest reliability assessment of the Italian language version of the PRO-CTCAE questionnaire that was developed in the first step, with a minimum of 59 Italian speaking patients to be enrolled. A validation study is planned and will be the subject of a separate protocol.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Translation and cross-cultural adaptation phase

In this phase 96 Italian-speaking patients who are receiving cancer treatment or who have completed treatment for cancer within the past six months at one of the participating sites will first be asked to independently complete a series of PRO-CTCAE symptom items in a Patient Questionnaire. Following completion by the participant of the Patient Questionnaire containing PRO-CTCAE items, the interviewer will elicit participants' feedback regarding item comprehension, symptomatic adverse event terms, attribute terms, 7-day recall period, and response options, via a semi-scripted cognitive debriefing interview developed to assure consistency across interviews.

No interventions assigned to this group

Test-retest phase

In this phase a minimum of 59 Italian-speaking patients who are receiving cancer treatment will be asked to independently complete the Italian version PRO-CTCAE questionnaire on 2 consecutive business days.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients receiving (or who have received within 6 months) chemotherapy or radiotherapy with curative or palliative intent for an advanced cancer at one of the study sites
* ≥18 years of age
* able to speak and understand Italian
* providing written informed consent


* ≥18 years of age.
* Patient is able to complete PRO-CTCAE on two consecutive days.
* Patient is actively receivingmedical treatment for cancer or has completed treatment not more than 4 weeks before Visit 1
* Any type of cancer
* Able to complete questionnaire by themselves or with assistance.
* Providing informed written consent.
* Able to speak and understand Italian

Exclusion Criteria

• Patients judged unable to report on their symptoms from the last seven days due to cognitive impairment.

Eligibility Criteria for Validation phase:


* Clinically significant cognitive or memory impairment in the opinion of clinical or research staff.
* Other important acute medical conditions that, in the opinion of the Investigator, may prevent compliance..
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute, Naples

OTHER

Sponsor Role collaborator

F.A.V.O. Italian Federation of Volunteer-Based Cancer Organizations

UNKNOWN

Sponsor Role collaborator

SmithKline Foundation

UNKNOWN

Sponsor Role collaborator

Parma University Hospital

OTHER

Sponsor Role collaborator

IRCCS AOU San Martino -IST Genoa

UNKNOWN

Sponsor Role collaborator

Istituti Ospitalieri di Cremona

OTHER

Sponsor Role collaborator

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER

Sponsor Role collaborator

Italian PRO-CTCAE Study Group

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Francesco Perrone

Role: PRINCIPAL_INVESTIGATOR

National Cancer Institute, Naples

Caterina Caminiti

Role: PRINCIPAL_INVESTIGATOR

Parma University Hospital

Michela Bagnalasta

Role: PRINCIPAL_INVESTIGATOR

Smith Kline Foundation

Fabio Arpinelli

Role: PRINCIPAL_INVESTIGATOR

Smith Kline Foundation

Maurizio Bassi

Role: PRINCIPAL_INVESTIGATOR

Smith Kline Foundation

Pierpaolo Betteto

Role: PRINCIPAL_INVESTIGATOR

F.A.V.O. Italian Federation of Volunteer-Based Cancer Organizations

Lucia Del Mastro

Role: PRINCIPAL_INVESTIGATOR

IRCCS AOU San Martino -IST, National Cancer Research Institute

Davide De Persis

Role: PRINCIPAL_INVESTIGATOR

F.A.V.O. Italian Federation of Volunteer-Based Cancer Organizations

Elisabetta Iannelli

Role: PRINCIPAL_INVESTIGATOR

F.A.V.O. Italian Federation of Volunteer-Based Cancer Organizations

Anna Lisa Nicelli

Role: PRINCIPAL_INVESTIGATOR

Smith Kline Foundation

Rodolfo Passalacqua

Role: PRINCIPAL_INVESTIGATOR

Istituti Ospitalieri Cremona

Camillo Porta

Role: PRINCIPAL_INVESTIGATOR

Fondazione I.R.C.C.S. Policlinico San Matteo

Jane Bryce

Role: PRINCIPAL_INVESTIGATOR

National Cancer Institute, Naples

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IRCCS Istituto Oncologico"Giovanni Paolo II"

Bari, , Italy

Site Status

Ospedale "A.Perrino"

Brindisi, , Italy

Site Status

Istituti Ospitalieri

Cremona, , Italy

Site Status

IRCCS AOU San Martino -IST

Genova, , Italy

Site Status

AOU Policlinico G.Martino

Messina, , Italy

Site Status

Istituto Nazionale Tumori

Milan, , Italy

Site Status

Istituto Nazionale Tumori - Fondazione Pascale

Napoli, , Italy

Site Status

Istituto Oncologico Veneto

Padua, , Italy

Site Status

IRCCS Policlinico S.Matteo

Pavia, , Italy

Site Status

A.O. Sant'Andrea

Roma, , Italy

Site Status

Ospedale San Camillo Forlanini

Roma, , Italy

Site Status

Policlinico Umberto I

Roma, , Italy

Site Status

Ospedale Civile SS.Annunziata

Sassari, , Italy

Site Status

Ospedale Valdelsa di Poggibonsi

Siena, , Italy

Site Status

AOU San Luigi Orbassano

Torino, , Italy

Site Status

Policlinico Universitario G.B.Rossi

Verona, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Italian PRO-CTCAE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cancer Fatigue Education Program
NCT01278147 COMPLETED NA
Patient Navigator Project
NCT00375024 COMPLETED NA